Carregant...
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
BACKGROUND: Patients with relapsed chronic lymphocytic leukemia (CLL) who have clinically significant coexisting medical conditions are less able to undergo standard chemo-therapy. Effective therapies with acceptable side-effect profiles are needed for this patient population. METHODS: In this multi...
Guardat en:
| Autors principals: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2014
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4161365/ https://ncbi.nlm.nih.gov/pubmed/24450857 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1315226 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|